Search

Sanofi SA

Fechado

SetorSaúde

81.04 0.07

Visão Geral

Variação de preço das ações

24h

Atual

Mín

80.98

Máximo

81.19

Indicadores-chave

By Trading Economics

Rendimento

3.9B

5.8B

Vendas

11B

21B

P/E

Médio do Setor

15.922

34.393

EPS

1.59

Rendimento de Dividendos

4.88

Margem de lucro

27.234

Funcionários

82,878

EBITDA

2.2B

2.8B

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+33.26% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

4.88%

2.54%

Próximos Ganhos

24 de out. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-4.1B

100B

Abertura anterior

80.97

Fecho anterior

81.04

Sentimento de Notícias

By Acuity

34%

66%

90 / 374 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Sanofi SA Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

4 de ago. de 2025, 10:06 UTC

Grandes Movimentos do Mercado

U.K. Bank Shares Rise After Car-Loan Ruling Softens Industry Blow -- Update

31 de jul. de 2025, 06:00 UTC

Ganhos

Sanofi Upbeat on Sales Outlook After Faster-Than-Expected Growth

30 de jul. de 2025, 10:20 UTC

Ganhos

Santander Reports Higher Profit, but Regional Picture is Mixed -- Update

30 de jul. de 2025, 05:31 UTC

Ganhos

Santander Sticks to Guidance, Launches $2 Billion Buyback After Profit Rises

6 de ago. de 2025, 05:02 UTC

Aquisições, Fusões, Aquisições de Empresas

Sanofi Completes the Acquisition of Vigil Neuroscience

6 de ago. de 2025, 05:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Press Release: Sanofi Completes The Acquisition Of Vigil Neuroscience, Inc. >SAN.FR

1 de ago. de 2025, 13:16 UTC

Ganhos

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1 de ago. de 2025, 12:40 UTC

Ganhos

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

31 de jul. de 2025, 08:15 UTC

Conversa de Mercado
Ganhos

Sanofi's Higher Costs Take Shine off Outlook Raise -- Market Talk

31 de jul. de 2025, 05:56 UTC

Conversa de Mercado
Ganhos

Sanofi in the Dark on Pharma Tariffs After U.S.-EU Deal -- Market Talk

31 de jul. de 2025, 05:30 UTC

Ganhos

Sanofi 2Q Vaccine Sales Increased 10% to EUR1.2B

31 de jul. de 2025, 05:30 UTC

Ganhos

Sanofi Says Pharma Launches Sales Increased by 40% in 2Q

31 de jul. de 2025, 05:30 UTC

Ganhos

Sanofi 2Q Dupixent Sales Grew 21% to EUR3.8B

31 de jul. de 2025, 05:30 UTC

Ganhos

Sanofi Intends to Complete EUR5B Buyback in 2025, With 80% Repurchased to Date

31 de jul. de 2025, 05:30 UTC

Ganhos

Sanofi: 2025 Business EPS Guidance Now Includes Expenses From Acquisitions

31 de jul. de 2025, 05:30 UTC

Ganhos

Sanofi 2Q Business Operating Profit EUR2.46B

31 de jul. de 2025, 05:30 UTC

Ganhos

Sanofi 2Q Adj EPS EUR1.59

31 de jul. de 2025, 05:30 UTC

Ganhos

Analysts Saw Sanofi 2Q Business Operating Profit at EUR2.57B

31 de jul. de 2025, 05:30 UTC

Ganhos

Analysts Saw Sanofi 2Q Net Sales at EUR9.77B

31 de jul. de 2025, 05:30 UTC

Ganhos

Sanofi 2Q Net Pft EUR3.94B

31 de jul. de 2025, 05:30 UTC

Ganhos

Analysts Saw Sanofi 2Q Business EPS at EUR1.64

31 de jul. de 2025, 05:30 UTC

Ganhos

Sanofi Now Expects 2025 Sales Growth at Constant Currency at High Single-Digit Percentage

31 de jul. de 2025, 05:30 UTC

Ganhos

Sanofi Had Seen 2025 Sales Growth at Constant Currency at Mid-To-High Single-digit

31 de jul. de 2025, 05:30 UTC

Ganhos

Sanofi 2Q Sales EUR9.99B

31 de jul. de 2025, 05:30 UTC

Ganhos

Sanofi Backs 2025 EPS Adj View

31 de jul. de 2025, 05:30 UTC

Ganhos

Sanofi Narrows 2025 Sales View

31 de jul. de 2025, 05:30 UTC

Ganhos

Sanofi Confirms Expectations of Business EPS Rebound in 2025 Before Buybacks

30 de jul. de 2025, 07:48 UTC

Conversa de Mercado
Ganhos

Santander Results Get Lukewarm Reaction -- Market Talk

30 de jul. de 2025, 06:41 UTC

Conversa de Mercado
Ganhos

Santander's Strategic Investments in Focus -- Market Talk

30 de jul. de 2025, 04:52 UTC

Ganhos

Santander End-2Q CET1 Ratio 13%

Comparação entre Pares

Variação de preço

Sanofi SA Previsão

Preço-alvo

By TipRanks

33.26% parte superior

Previsão para 12 meses

Média 107.845 EUR  33.26%

Máximo 124 EUR

Mínimo 90 EUR

Com base em 14 analistas de Wall Street que oferecem metas de preço de 12 meses para Sanofi SA - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

14 ratings

10

Comprar

4

Manter

0

Vender

Pontuação Técnica

By Trading Central

91.3 / 96.1Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Strong Bearish Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

90 / 374 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.